Gortman Aron, Aherne Noel J, Westhuyzen Justin, Amalaseelan Julan V, Dwyer Patrick M, Hoffmann Matthew, Last Andrew T, Shakespeare Thomas P
Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales 2450, Australia.
Rural Clinical School, Faculty of Medicine, University of New South Wales, New South Wales 2450, Australia.
Mol Clin Oncol. 2021 Sep;15(3):178. doi: 10.3892/mco.2021.2340. Epub 2021 Jul 1.
Metaplastic breast carcinoma is an uncommon subtype of invasive ductal carcinoma with a tendency towards poorer clinical outcomes. Following ethical approval, the current study reviewed the institutional records of ~2,500 women with breast cancer. A total of 14 cases of metaplastic breast cancer were reviewed for management and treatment outcomes. The results demonstrated that patients had median follow up of 30 months, a 5-year disease-free survival of 57.1% and 5-year overall survival of 57.1%. The majority of patients had at least T2 disease and all tumours were high grade. Additionally, most patients were triple negative and nodal metastases were uncommon. Metaplastic breast cancer is an aggressive variant of invasive breast cancer. Most patients can be treated with breast conservation and survival parameters tend to be worse than more common breast cancer subtypes.
化生性乳腺癌是浸润性导管癌的一种罕见亚型，临床预后往往较差。在获得伦理批准后，本研究回顾了约2500例乳腺癌女性患者的机构记录。共对14例化生性乳腺癌患者的治疗及治疗结果进行了回顾。结果显示，患者的中位随访时间为30个月，5年无病生存率为57.1%，5年总生存率为57.1%。大多数患者至少患有T2期疾病，所有肿瘤均为高级别。此外，大多数患者为三阴性，淋巴结转移并不常见。化生性乳腺癌是浸润性乳腺癌的一种侵袭性变体。大多数患者可采用保乳治疗，但其生存参数往往比更常见的乳腺癌亚型更差。
